BACKGROUND - The objective of the current study was to test generalizability and clinical value of a recently published nomogram to predict specimen-confined disease (SCD, pT2-pT3a+R0+pN0) at radical prostatectomy (RP) in patients with clinical high-risk prostate cancer (HRPCa). The nomogram allows improved decision making with curative intent within this heterogeneous patient cohort, which is important, as RP in patients with clinical HRPCa remains a topic of controversy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS - We externally validated the nomogram in 1,669 men with clinical HRPCa who underwent RP and extended pelvic lymph node dissection between 1992 and 2011. A Kaplan-Meier analysis to estimate 5- and 10-year biochemical recurrence-free survival was performed. To investigate the SCD model׳s performance, the previously reported regression coefficients of the SCD nomogram were applied. Within loess calibration plots, the extent of overestimation or underestimation was graphically explored. Finally, decision curve analysis (DCA) to assess the clinical value of the SCD nomogram was performed.
RESULTS - Overall, 49% of men showed SCD after RP. The 5- and 10-year biochemical recurrence rates for men with SCD were 66% and 56%, respectively, vs. 32% and 20%, respectively, for men without SCD (log-rank test P<0.001). External validation demonstrated comparable accuracy in relation to accuracy derived from internal validation (68.1% vs. 72.0%). Calibration was suboptimal, showing a tendency to underestimate SCD probability. In DCA, the nomogram׳s usage was associated with a clinical net benefit relative to both treating all and none.
CONCLUSIONS - Within our cohort, the nomogram׳s use was associated with a clinical net benefit according to DCA. However, one-third of men were falsely classified as having SCD or non-SCD. Nevertheless, in the absence of superior tools, the SCD nomogram represents a useful clinical decision aid.
Urol Oncol. 2015 Jun 26. pii: S1078-1439(15)00150-7. doi: 10.1016/j.urolonc.2015.02.017. [Epub ahead of print]
Hansen J1, Becker A2, Kluth LA3, Rink M3, Steuber T4, Zacharias M5, Briganti A6, Fisch M3, Graefen M4, Chun FK2.
1 Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany.
2 Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Martini Clinic, Prostate Cancer Centre at University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
3 Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
4 Martini Clinic, Prostate Cancer Centre at University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
5 Department of Urology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany.
6 Department of Urology, Vita-Salute San Raffaele University, Milan, Italy.